Ann: Investor Webinar on Acquisition of License for Azer-cel, page-282

That's fine. I think it is a great addition. Strategically I think it is great and I can see the LT potential.

I am simply saying, that when IMU have been stating (in answer to questions re commercialisation strategy) for last 2 years + time and time again, something like; "we do not intend to commercialise anything ourselves, our strategy is to get to end of Phase 2 then licence/get bought out etc." Then you say from today onwards (yesterday) "commercialisation independently, is now an options". We can argue about the language, but it is a clear change in strategy, that's all.

That is not to say this is a great deal that they had to jump on (due to timing of precision' s situation etc), and is very good for our goals with CF33 and Oncarlytics, I can see all that.

I would have preferred, just an acknowledgement, that yep we changed direction, we changed strategy, cause things change and opportunities come up, and so-on. (LC almost kinda said that in the webinar).

Anyways - overall happy with the LT goals.